Comparator: atorvastatin

DRUG11 trials

Sponsors

Organon and Co, Sunnybrook Health Sciences Centre, Merck Sharp & Dohme LLC

Conditions

Atherosclerotic DiseaseCoronary DiseaseDyslipidemiaHypercholesterolemiaType 2 Diabetes Mellitus

Phase 1

The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)

CompletedNCT00990808

Merck Sharp & Dohme LLCDyslipidemia

Start: 2009-11-30End: 2011-07-31Updated: 2015-06-04

Phase 2

A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)

CompletedNCT00977288

Merck Sharp & Dohme LLCDyslipidemia

Start: 2009-09-30End: 2014-04-30Updated: 2015-05-06

Phase 3

Cholesterol Lowering Level of MK0653A+Simvastatin in Patients With Hypercholesterolemia and Atherosclerotic or Coronary Vascular Disease (0653A-806)(COMPLETED)

CompletedNCT00090168

Organon and CoAtherosclerotic Disease, Coronary Disease, Hypercholesterolemia

Start: 2004-01-27End: 2004-11-10Updated: 2024-08-15

MK0653A (Ezetimibe (+) Simvastatin) Compared to an Approved Drug (Atorvastatin) for the Treatment of High Cholesterol (0653A-051)(COMPLETED)

CompletedNCT00092690

Organon and CoHypercholesterolemia

Start: 2003-06-30End: 2004-03-31Updated: 2024-05-10

A Multicenter Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Products in Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia (MK-0653A-077)

CompletedNCT00110435

Organon and CoHypercholesterolemia, Type 2 Diabetes Mellitus

Start: 2005-05-31End: 2005-12-31Updated: 2024-08-15

A 12 Week Study of MK0653A in Patients Who Have Been Hospitalized for a Possible Heart Problem (0653A-808)

CompletedNCT00132717

Organon and CoHypercholesterolemia

Start: 2005-01-01End: 2007-06-01Updated: 2024-08-15

To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 20 mg (0653-079)(COMPLETED)

CompletedNCT00276458

Organon and CoHypercholesterolemia

Start: 2006-02-28End: 2008-01-31Updated: 2024-05-13

A Study to Determine the Number of Patients Who Reach Optimal Cholesterol Levels on Each of Three Different Treatments (0653A-121)

CompletedNCT00462748

Organon and CoHypercholesterolemia

Start: 2007-03-31End: 2008-06-30Updated: 2024-05-16

A Multicenter, Randomized, Open Label Study to Evaluate the Lipid Lowering Efficacy and Safety of Vytorin® 10/20 vs. Atorvastatin 10mg in Hypercholesterolemia Patients With Metabolic Syndrome in Korea (0653A-129)(COMPLETED)

CompletedNCT00496730

Organon and CoHypercholesterolemia

Start: 2007-07-31End: 2008-08-31Updated: 2024-05-16

INdians Followed for INtensive Lipid Lowering Treatment and Its safetY

TerminatedNCT00664469

Sunnybrook Health Sciences CentreHypercholesterolemia

Start: 2007-08-31End: 2010-11-30Updated: 2011-07-28

Phase 4

Vytorin (10/20 Or 10/40) Compared to Atorvastatin (10 mg or 20 mg) in Patients With Coronary Artery Disease (0653A-126)(COMPLETED)

CompletedNCT00442897

Organon and CoHypercholesterolemia

Start: 2006-09-30End: 2008-10-31Updated: 2024-05-22

Related Papers

CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects

Arteriosclerosis Thrombosis and Vascular Biology2017-07-2193 citations

Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects.

2015-05-1162 citations